Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
TORONTO, April 10, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX:AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of its observational real-world evidence (“RWE”) study using RHO Phyto branded cannabigerol (“CBG”) transdermal gel on patients with musculoskeletal pain and inflammation.